secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-06-29T12:11:25+00:00
Accession:  0001104659-26-078511
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports Q4 loss of $73.7M; FDA accepts RP1 BLA resubmission for advanced melanoma
--------------------------------------------------------------------------------

- Net loss $73.7M in Q4 FY2026; full-year net loss $313.9M.
- FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA Aug 2, 2026, advisory cttee in late July.
- Cash $268.9M at March 31, 2026; expected runway into Q1 calendar 2027.
- IGNYTE-3 (Phase 3) and REVEAL (Phase 2/3) trials enrolling; REVEAL Phase 2/3 transition expected Q1 2027.
- ASCO 2026: RP1+nivo 3-yr OS 47.8%, median OS 32.9 mos; RP2 19% ORR in solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/0001104659-26-078511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer